pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
siRNA · news · pharmadog
← back to siRNA
News · siRNA
111
stories
2d
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
biospace
2d
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
biopharma dive
2d
Regeneron enters neurology field as FDA approves siRNA for myasthenia gravis
endpoints
4d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
4d
5 acquisitions that forced Big Pharmas to co-parent
biospace
5d
Marrow raises $173M for siRNA drug competing with CRISPR therapy for sickle cell
endpoints
5d
Marrow sets out to challenge genetic medicines for severe blood diseases
biopharma dive
5d
ObesityWeek 2026: Wave outlines case for body composition–based trial design
biospace
6d
Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
biospace
8d
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
biospace
9d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
9d
Deep dive: Cardiovascular calamities and catalysts
biospace
12d
Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
biospace
12d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
15d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
15d
Sarepta’s new CEO confident in clinical execution as DMD competitors close in
biospace
17d
AHA: Novartis’ Lp(a) drug shows zero benefit, casting shadow over Amgen and Lilly programs
fiercebiotech
20d
BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
biospace
22d
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
biospace
23d
Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
biospace
23d
‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise
biospace
29d
This week in charts: a big year for RNAi developers
biopharma dive
29d
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
biospace
Oct 22, 26
Chutes & Ladders—Troubled CSL enlists GSK vet Deborah Waterhouse to lead
fiercebiotech
Oct 22, 26
Biotech notches 31 IPOs already this year, with 4 more joining queue
biospace
Oct 22, 26
GSK, Ionis hepatitis B functional cure breaks open market for followers
biospace
Oct 21, 26
GSK, Ionis win FDA nod for hepatitis B functional cure that controls virus after treatment
biospace
Oct 21, 26
Amid bepirovirsen triumph, GSK quietly scraps trial of next-gen hep B therapy
fiercebiotech
Oct 21, 26
The 6 biggest crossover rounds in biopharma history
biospace
Oct 20, 26
Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform
biospace
← prev
page 1 of 4
next →